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shere has been a significant movement re-
cently in a rather stagnant field of cardiovascular
radionuclide imaging in the U.S. Two relatively
large prospective clinical studies have just
een completed with 123I-labeled beta-methyl-p-
odophenyl-pentadecanoic acid and 123I-labeled meta-
odobenzylguanidine (mIBG) for the assessment of
schemic memory and neuronal dysfunction, respec-
ively. The results of these studies have been recently
resented (1,2). A third agent, 18F-labeled pyridaben
erivative, is also being investigated in a large clinical
rial for myocardial perfusion imaging (3). However,
efore such tests are incorporated into the routine
linical practice, it would be mandatory to demon-
trate that the management strategy including the
ovel imaging tools is distinctly superior to the stan-
ard of care.
Molecular imaging with mIBG, a false adrenergic
eurotransmitter, was proposed for the assessment of
he sympathetic neuronal system years ago (4) and
epresents one of the few imaging agents that has
ndured the arduous scientific journey from bench to
edside. mIBG shares the reuptake mechanism and
ndogenous storage with norepinephrine but is nei-
her metabolized nor does it interact with post-
ynaptic receptors. Images of the heart acquired with
adiolabeledmIBG provide sufficient spatial resolution
o provide both anatomic localization and quantifiable
unctional attributes. 123I-mIBG was approved with a
ardiac indication in Japan more than 15 years ago and
as been used clinically with an established safety
ecord. In Europe, it has been used almost for the
ame duration for assessing candidacy for cardiac
ransplantation. mIBG has received U.S. Food and
rom the *University of Maryland Medical Center, Baltimore, Maryland;
University of Minnesota VA Medical Center, Minneapolis, Minnesota;s
nd the ‡Memorial Heart and Vascular Institute and University of
alifornia, Irvine, California.rug Administration (FDA) approval for imaging
euroendocrine tumors in the U.S. However, for the
outine characterization of neuronal function in the
eart, the FDA had requested 2 well-controlled trials
o demonstrate that mIBG imaging results are indeed
redictive of outcome in heart failure (HF) patients.
he prospective evaluation was deemed necessary,
ecause it was not available from the trial used to
btain approval in Japan, and the European approval
as based only on literature but not on the prospective
rial data.
As such, 2 multinational prospective open-label,
ulticenter, phase 3 studies evaluating the usefulness
f 123I-mIBG imaging to identify symptomatic HF
atients who are likely to experience a major adverse
ardiac event (ADMIRE-HF [AdreView Myocardial
maging for Risk Evaluation in Heart Failure] study)
ere performed (1). Almost 1,000 subjects with HF
New York Heart Association [NYHA] functional
lass II to III; left ventricular ejection fraction 35%)
ere recruited and followed for up to 2 years until the
ime to first occurrence of NYHA functional class
rogression, potentially life-threatening arrhythmic
vent (including implantable cardioverter-defibrillator
ICD] discharge), or cardiac death. Adverse events
ccurred in one-quarter of the patients; a 2-year
vent-free survival was 85% in subjects with normal
IBG uptake compared with 63% in subjects with
bnormal imaging result (hazard ratio [HR]: 0.40; p
0.001). HR for occurrence of HF progression,
rrhythmic events, and cardiac death were all individ-
ally significant (HR: 0.49, p 0.002; 0.37, p 0.02;
nd 0.14, p  0.006, respectively). Significant con-
ributors to the multivariable model were the mIBG
esults, left ventricular ejection fraction, B-type natri-
retic peptide, and NYHA functional class. This
tudy validated information gathered from numerous
maller and single-center studies reported earlier (5).
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118he results of the prospective study suggested that a
ubset of patients who are likely to worsen rapidly or die
sudden death and would benefit from aggressive treat-
ent, could be differentiated from those who do well.
Despite the reproducible benefits of aggressive
anagement, such as with resynchronization and
efibrillator device implantations, a large proportion
f appropriately selected patients are not benefited. As
uch, the most appropriate and cost-effective applica-
ion for a test such as mIBG would be to correctly
dentify patients who may benefit most from aggres-
ive HF therapy including biventricular pacing to
revent progression to end-stage disease, and to select
atients most deserving of a defibrillator insertion to
revent sudden arrhythmic deaths (6). With such an
nd in view, an mIBG single-photon emission com-
uted tomography study was recently performed in
00 HF patients to address the predictability of
ife-threatening tachyarrhythmias for an appropriate
CD indication (7). In a 2-year follow-up period, an
ppropriate ICD discharge was documented in 20%
f the patients and the mIBG defect score was an
ndependent predictor. Patients with greater defect
cores showed a 10-fold higher likelihood of appro-
riate ICD discharge therapy (50% vs. 5%, p  0.01)
han patients with smaller defects. The clinical trials of
esynchronization and defibrillator therapy are cur-
ently recruiting patients with relatively mild HF, and
uch a trend is likely to substantially add to the cost of
he health care expenditure. As such, the identification
f subjects at high risk and deserving of high-cost
evices has become significantly more important.
Assessment of the subclinical neuronal involvement
ay be relatively difficult and may require induction
f neuronal stress. It has been proposed that com-
etitive interference with the reuptake mechanism
ould accentuate mIBG defects and unmask sub-
linical dysfunction (8). Tricyclic antidepressants, such
s amitriptyline, are bonafide inhibitors of hu-
an norepinephrine transporter 1–norepinephrine-
ependent uptake in pre-synaptic neurons. A very
mall oral dose (25 mg) of amitriptyline was used in a
mall study of post-pharmacologic stress mIBG im-
ging in 6 patients. These patients had demonstrated
normal cardiac mIBG scan within the past week
uring work-up for movement disorders, and the
erial imaging was performed 4 h after amitriptyline to
ssess any change in the regional mIBG distribution.ean percentage of peak activity was calculated for Each segment at rest and after pharmacologic stress; a
10% decrease in regional mIBG uptake was ob-
erved in 20% of myocardial segments. Whether
ncovering such subclinical regional myocardial neu-
onal defects will identify subjects who are at a greater
isk for developing HF in the future is yet to be
etermined. However, this strategy may parallel the
linical and prognostic implications of myocardial
erfusion defects that are identified only with stress.
The role of neuronal imaging has also been ex-
lored for better decision making in specifically de-
igned boutique studies. An mIBG study (9), pre-
ented in the current issue of iJACC, proposes that
ormalization of mIBG uptake may allow identifica-
ion of subjects who have recovered from advanced
F and may be weaned from left ventricular assist
evices. This study, in addition to providing patient-
pecific information also offers in vivo clarification of
he pathogenetic mechanisms involved in adverse
nd reverse cardiac remodeling (10).
The new face of imaging is likely to be the
dentification of molecular targets—not as a
arker of disease alone but also as a maker to
dentify selected subpopulations that might bene-
t from specific therapies and more importantly,
uide such therapies. Techniques such as neuronal
maging may have the promise of offering some
olutions to clinical problems that have defied
lassification with current techniques. The poten-
ial of new tests may only be realized once these
ests become clinically available for innovative,
nvestigator-initiated clinical studies providing im-
roved disease definition, more intelligent choice
f therapeutic intervention, and closer monitoring
f response to therapeutic interventions. Thus, a
ebate is timely to compare the pros and cons of
stablishing all indications of a new test before it
s approved by a regulatory process versus ap-
roval of a test (once proven to be safe in human
se) to allow investigators to study its potential in
umerous clinically relevant conditions.
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